Celcuity

Celcuity R&D Expenses

The Research & Development Expenses of Celcuity (CELC) as of Nov 11, 2026 is 145.00 M USD. In the previous year, Research & Development Expenses was 104.20 M USD — a change of 39.15% (higher).

R&D Expenses

145.00 MUSD

YoY

39.15%

Last updated:

Research & Development Expenses of Celcuity is 2025 145.00 M USD. Research & Development Expenses of Celcuity was 2024 104.20 M USD. It decreases by 39.15% higher compared to the previous year.

The Celcuity R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
6.33 M USD
Jan 1, 2019
6.27 M USD
Jan 1, 2020
7.68 M USD
Jan 1, 2021
25.76 M USD
Jan 1, 2022
35.29 M USD
Jan 1, 2023
60.59 M USD
Jan 1, 2024
104.20 M USD
Jan 1, 2025
145.00 M USD
The Celcuity R&D Expenses history
YEARR&D ExpensesYoY
145.00 MUSD+39.15%
104.20 MUSD+71.97%
60.59 MUSD+71.71%
35.29 MUSD+37.00%
25.76 MUSD+235.24%
7.68 MUSD+22.56%
6.27 MUSD-0.90%
6.33 MUSD+27.02%
4.98 MUSD+62.51%
3.06 MUSD+52.35%
2.01 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Research & Development Expenses of Celcuity is 145.00 M USD in 2025.

Research & Development Expenses of Celcuity changed from 104.20 M USD to 145.00 M USD, representing a 39.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Celcuity since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Celcuity

All Key Metrics — Celcuity